Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.


AIMS This 24-week, randomized, multicentre, open-label, parallel-group clinical trial compared efficacy and safety of repaglinide monotherapy, rosiglitazone monotherapy, and combination therapy (repaglinide plus rosiglitazone) in Type 2 diabetes after unsatisfactory response to sulphonylurea or metformin monotherapy. METHODS Enrolled patients (n = 252… (More)


Cite this paper

@article{Raskin2004CombinationTF, title={Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.}, author={Paul Raskin and Julie McGill and Mohammed Saad and John Cappleman and Wendy E. Kaye and Naum M. Khutoryansky and Paula M. Hale}, journal={Diabetic medicine : a journal of the British Diabetic Association}, year={2004}, volume={21 4}, pages={329-35} }